SLS Share Price | SELLAS Life Sciences Group, Inc. Stock Analysis & Recommendation

Q: How big is SELLAS Life Sciences Group, Inc.?

Market Cap: As of Jun 18, SELLAS Life Sciences Group, Inc. has a market capitalization of 155.65 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -27.13 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 9.46 million, while total assets were reported at 19.63 million.

Q: What does SELLAS Life Sciences Group, Inc. do?

Overview:SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapeutics in the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025)Market cap: USD 155.65 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.01Return on Equity: -97.73%Price to Book: 5.61Contact Details:Address: 7 TIMES SQUARE, SUITE 2503, NEW YORK NY: 10036Tel: 1 646 2005278Fax: 1 925 4987799Website: https://www.sellaslifesciences.com/

Q: Is SELLAS Life Sciences Group, Inc. overvalued or undervalued?

As of 11 May 2023, the valuation grade for SELLAS Life Sciences Group, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its financial metrics, with a Price to Book Value of 5.79 and a Return on Equity (ROE) of -97.73%. Additionally, the EV to EBITDA and EV to EBIT ratios are both negative at -4.75, reflecting the company's loss-making status.In comparison to peers, SELLAS Life Sciences Group, Inc. has a worse EV to EBITDA ratio than Rezolute, Inc. at -3.4613 and Assembly Biosciences, Inc. at -0.8977, both of which are also categorized as risky. The company's recent stock performance shows a 64.42% year-to-date return, which outperforms the S&P 500's 2.44%, yet this does not mitigate the overall valuation concerns. Therefore, based on the analysis, SELLAS Life Sciences Group, Inc. is considered overvalued.

Q: Is SELLAS Life Sciences Group, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for SELLAS Life Sciences Group, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands on a weekly basis are bearish, contrasting with the monthly view which is mildly bullish. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum.In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -14.81% and -6.94% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has significantly outperformed the benchmark with a return of 54.81% compared to the S&P 500's 12.22%.

Results Declared: SELLAS Life Sciences Group, Inc. has declared results on 19 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

29.21 M

Shareholding (Dec 2025)

FII

1.79%

Held by 23 FIIs

DII

86.07%

Held by 16 DIIs

Promoter

0.00%

How big is SELLAS Life Sciences Group, Inc.?

22-Jun-2025

As of Jun 18, SELLAS Life Sciences Group, Inc. has a market capitalization of 155.65 million, with net sales of 0.00 million and a net profit of -27.13 million over the latest four quarters. The company's shareholder's funds are 9.46 million, and total assets amount to 19.63 million.

View full answer

What does SELLAS Life Sciences Group, Inc. do?

22-Jun-2025

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing targeted oncology therapeutics. As of March 2025, it has a market cap of $155.65 million and reported a net profit loss of $6 million.

View full answer

Who are in the management team of SELLAS Life Sciences Group, Inc.?

22-Jun-2025

As of March 2022, the management team of SELLAS Life Sciences Group, Inc. includes Ms. Jane Wasman (Independent Chairman), Dr. Angelos Stergiou (President and CEO), Dr. David Scheinberg (Director), and Independent Directors Mr. Robert Van Nostrand and Mr. John Varian. They are responsible for the company's strategic direction and operations.

View full answer

Is SELLAS Life Sciences Group, Inc. overvalued or undervalued?

25-Jun-2025

SELLAS Life Sciences Group, Inc. is considered overvalued due to a significant downgrade in its investment appeal, reflected by a Price to Book Value of 5.79, a negative Return on Equity of -97.73%, and negative EV to EBITDA and EV to EBIT ratios, despite a strong year-to-date stock performance of 64.42%.

View full answer

Is SELLAS Life Sciences Group, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, SELLAS Life Sciences Group, Inc. shows a mildly bullish trend with daily moving averages indicating positivity, but caution is advised due to bearish weekly MACD and KST, while the stock has underperformed the S&P 500 recently but significantly outperformed it year-to-date.

View full answer

Compare SELLAS Life Sciences Group, Inc. with Similar Stocks

Assembly Biosciences, Inc.Rezolute, Inc.MEI Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 763 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.96

Return on Equity

-56.85%

Price to Book

16.73

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

103.42%

6 Months

195.65%

1 Year

340.74%

2 Years

353.33%

3 Years

252.59%

4 Years

-32.48%

5 Years

-54.84%

SELLAS Life Sciences Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-14.46%

EBIT to Interest (avg)

-27.64

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.19

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

28.70%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.73

EV to EBIT

-26.72

EV to EBITDA

-26.72

EV to Capital Employed

397.83

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1489.05%

ROE (Latest)

-56.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 15 Schemes (12.14%)

Foreign Institutions

Held by 23 Foreign Institutions (1.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -13.24% vs -3.03% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-7.10",
          "chgp": "-16.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.70",
          "val2": "-6.80",
          "chgp": "-13.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 12.94% vs 17.16% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.30",
          "val2": "-31.50",
          "chgp": "10.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.90",
          "val2": "-30.90",
          "chgp": "12.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.30

-7.10

-16.90%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.70

-6.80

-13.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -13.24% vs -3.03% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.30

-31.50

10.16%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-26.90

-30.90

12.94%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 12.94% vs 17.16% in Dec 2024

All Annual Results

Company CV

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

Pharmaceuticals & Biotechnology

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Company Coordinates

Company Details

7 TIMES SQUARE, SUITE 2503 , NEW YORK NY : 10036

Tel: 1 646 2005278

https://www.sellaslifesciences.com/

Registrar Details